Skip Navigation LinksHome > December 2013 - Volume 258 - Issue 6 > Recombinant Human Thrombomodulin Suppresses Experimental Abd...
Annals of Surgery:
doi: 10.1097/SLA.0b013e31827df7cb
Original Articles

Recombinant Human Thrombomodulin Suppresses Experimental Abdominal Aortic Aneurysms Induced by Calcium Chloride in Mice

Lai, Chao-Han MD*,†,‡; Shi, Guey-Yueh PhD†,§; Lee, Fang-Tzu MS†,§; Kuo, Cheng-Hsiang PhD†,§; Cheng, Tsung-Lin PhD†,§; Chang, Bi-Ing MS†,§; Ma, Chih-Yuan PhD†,§; Hsu, Fu-Chih MS†,§; Yang, Yu-Jen MD, PhD†,‡; Wu, Hua-Lin PhD†,§

Supplemental Author Material
Collapse Box

Abstract

Objective: To investigate whether recombinant thrombomodulin containing all the extracellular domains (rTMD123) has therapeutic potential against aneurysm development.

Summary Background Data: The pathogenesis of abdominal aortic aneurysm (AAA) is characterized by chronic inflammation and proteolytic degradation of extracellular matrix. Thrombomodulin, a transmembrane glycoprotein, exerts anti-inflammatory activities such as inhibition of cytokine production and sequestration of proinflammatory high-mobility group box 1 (HMGB1) to prevent it from engaging the receptor for advanced glycation end product (RAGE) that may sustain inflammation and tissue damage.

Methods: The in vivo effects of treatment and posttreatment with rTMD123 on aortic dilatation were measured using the CaCl2-induced AAA model in mice.

Results: Characterization of the CaCl2-induced model revealed that HMGB1 and RAGE, both localized mainly to macrophages, were persistently upregulated during a 28-day period of AAA development. In vitro, rTMD123-HMGB1 interaction prevented HMGB1 binding to macrophages, thereby prohibiting activation of HMGB1-RAGE signaling in macrophages. In vivo, short-term treatment with rTMD123 upon AAA induction suppressed the levels of proinflammatory cytokines, HMGB1, and RAGE in the aortic tissue; reduced the infiltrating macrophage number; and finally attenuated matrix metalloproteinase production, extracellular matrix destruction, and AAA formation without disturbing vascular calcification. Consistently, posttreatment with rTMD123 seven days after AAA induction alleviated vascular inflammation and retarded AAA progression.

Conclusions: These data suggest that rTMD123 confers protection against AAA development. The mechanism of action may be associated with reduction of proinflammatory mediators, blockade of macrophage recruitment, and suppression of HMGB1-RAGE signaling involved in aneurysm formation and downstream macrophage activation.

© 2013 by Lippincott Williams & Wilkins.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.